Market News / Story
Ribo Files EU CTA For Phase 1 Study Of RBD3133
·
Ribo submitted a European Clinical Trial Application for a Phase 1 study of RBD3133, an siRNA targeting INHBE. Material Details #DetailAI Analyst View1EU CTA filed for RBD3133 Phase 1Regulatory step enabling first-in-human testing; can re-rate pipeline odds.2Target: INHBE via siRNANovel target/modality may address metabolic pathways; raises optionality. Context by AI Analyst This is an early-stage pipeline milestone indicating movement toward first-in-human testing. A…